11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Levodopa/Benserazid Orifarm

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C! C!
C! C!

Levodopa + enzymhämmare (benserazid, karbidopa, entakapon)

Levodopa + enzymhämmare (benserazid, karbidopa, entakapon)

Klass : C!

Visa all info

Skriv ut

Kontakta oss

  1. Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: A clinical perspective. Acta Neurol Scand. 2017;136(6):570-584.

  2. Arabia G, Zappia M, Bosco D, Crescibene L, Bagalà A, Bastone L et al. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurol Sci. 2002;23 Suppl 2:S53-4.

  3. Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2010;16:490-7.

  4. Zappia M, Crescibene L, Arabia G, Nicoletti G, Bagalà A, Bastone L et al. Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol. 2002;25:79-82.

  5. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002;58(9):1418-22.

  6. Martinelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?. Neurol Sci. 2003;24:192-3.

  7. Kumagai T, Nagayama H, Ota T, Nishiyama Y, Mishina M, Ueda M. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol. 2014;37(6):173-6.

  8. Nyholm D, Karlsson E, Lundberg M, Askmark H. Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women. Eur J Neurol. 2010;17:260-6.

  9. Baba Y, Putzke JD, Whaley NR, Wszolek ZK, Uitti RJ. Gender and the Parkinson's disease phenotype. J Neurol. 2005;252:1201-5.

  10. Altmann V, Schumacher-Schuh AF, Rieck M, Callegari-Jacques SM, Rieder CR, Hutz MH. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease. Pharmacogenomics. 2016;17(5):481-8.

  11. Hassin-Baer S, Molchadski I, Cohen OS, Nitzan Z, Efrati L, Tunkel O et al. Gender effect on time to levodopa-induced dyskinesias. J Neurol. 2011;258:2048-53.

  12. Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005;62:601-5.

  13. Kaasinen V, Nurmi E, Brück A, Eskola O, Bergman J, Solin O et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain. 2001;124:1125-30.

  14. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205-13.

  15. Murialdo G, Masturzo P, Carolei A, Polleri A. Dose and sex related effects of benserazide on prolactin secretion. Boll Soc Ital Biol Sper. 1979;55:373-7.

  16. Polleri A, Masturzo P, Murialdo G, Carolei A. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans. Acta Endocrinol (Copenh). 1980;93:7-12.

  17. Stalevo (levodopa, carbidopa, entacapone). DailyMed [www]. [updated 2020-01-07, cited 2020-01-16].

  18. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]

  1. Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: A clinical perspective. Acta Neurol Scand. 2017;136(6):570-584.
  2. Arabia G, Zappia M, Bosco D, Crescibene L, Bagalà A, Bastone L et al. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurol Sci. 2002;23 Suppl 2:S53-4.
  3. Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat Disord. 2010;16:490-7.
  4. Zappia M, Crescibene L, Arabia G, Nicoletti G, Bagalà A, Bastone L et al. Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol. 2002;25:79-82.
  5. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ et al. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology. 2002;58(9):1418-22.
  6. Martinelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?. Neurol Sci. 2003;24:192-3.
  7. Kumagai T, Nagayama H, Ota T, Nishiyama Y, Mishina M, Ueda M. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol. 2014;37(6):173-6.
  8. Nyholm D, Karlsson E, Lundberg M, Askmark H. Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women. Eur J Neurol. 2010;17:260-6.
  9. Baba Y, Putzke JD, Whaley NR, Wszolek ZK, Uitti RJ. Gender and the Parkinson's disease phenotype. J Neurol. 2005;252:1201-5.
  10. Altmann V, Schumacher-Schuh AF, Rieck M, Callegari-Jacques SM, Rieder CR, Hutz MH. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease. Pharmacogenomics. 2016;17(5):481-8.
  11. Hassin-Baer S, Molchadski I, Cohen OS, Nitzan Z, Efrati L, Tunkel O et al. Gender effect on time to levodopa-induced dyskinesias. J Neurol. 2011;258:2048-53.
  12. Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol. 2005;62:601-5.
  13. Kaasinen V, Nurmi E, Brück A, Eskola O, Bergman J, Solin O et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain. 2001;124:1125-30.
  14. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205-13.
  15. Murialdo G, Masturzo P, Carolei A, Polleri A. Dose and sex related effects of benserazide on prolactin secretion. Boll Soc Ital Biol Sper. 1979;55:373-7.
  16. Polleri A, Masturzo P, Murialdo G, Carolei A. Dose and sex related effects of aromatic aminoacids decarboxylase inhibitors on serum prolactin in humans. Acta Endocrinol (Copenh). 1980;93:7-12.
  17. Stalevo (levodopa, carbidopa, entacapone). DailyMed [www]. [updated 2020-01-07, cited 2020-01-16].
  18. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]